Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab

BACKGROUND: Multicentric Castleman’s disease (MCD) is a rare lymphoproliferative disorder driven by dysregulated interleukin-6 production. MCD has a poor prognosis, and treatment is generally noncurative and aimed at symptom relief. Siltuximab is a novel, monoclonal interleukin-6 antibody recently s...

Descripción completa

Detalles Bibliográficos
Autores principales: van Rhee, Frits, Rothman, Margaret, Ho, Kai Fai, Fleming, Sarah, Wong, Raymond S., Fosså, Alexander, Dispenzieri, Angela, Cavet, James, Munshi, Nikhil, Vermeulen, Jessica, Casper, Corey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383814/
https://www.ncbi.nlm.nih.gov/pubmed/25736164
http://dx.doi.org/10.1007/s40271-015-0120-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383814/
https://www.ncbi.nlm.nih.gov/pubmed/25736164
http://dx.doi.org/10.1007/s40271-015-0120-5

Ejemplares similares